Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapies

Chhabra, Amit; Bashirians, George; Petropoulos, Christos J.; Wrin, Terri; Paliwal, Yuvika; Henstock, Peter V.; Somanathan, Suryanarayan; da Fonseca Pereira, Candida; Winburn, Ian; Rasko, John E.J.

doi:10.1016/j.omtm.2024.101273

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article4

Preprint1

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 8 publications

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Seroprevalence of adeno-associated virus types 1, 2, 3, 4, 5, 6, 8, and 9 in a Basque cohort of healthy donors

Navarro-Oliveros,

Vidaurrazaga,

Soares Guerra

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Adeno-associated viruses (AAVs) are promising gene therapy vectors, but challenges arise when treating patients with preexisting neutralizing antibodies. Worldwide seroprevalence studies provide snapshots of existing immunity in diverse populations. Owing to the uniqueness of the Basque socio-geographical landscape, we investigated the seroprevalence of eight AAV serotypes in residents of the Basque Country. We found the highest seroprevalence of AAV3, and the lowest seroprevalence of AAV9. Additionally, less than 50% of the Basque population has neutralizing antibodies against AAV4, AAV6, and AAV9. Our findings provide insight into AAV infections in the Basque region, public health, and the development of AAV-based therapeutics.

show abstract